Quick Facts

• Primary Therapeutic Domain: Prostate cancer.
• Condition Addressed: Advanced prostate cancer that has metastasized (spread).
• Key Usage: Utilized in combination with an LHRH analog (such as goserelin or leuprolide) as part of a therapeutic regimen.

---

What Prostafine Treats: Main Uses and Benefits

Prostafine is a prescription medication indicated for the management of advanced prostate cancer that has spread to other parts of the body. It is typically administered as a component of combination therapy alongside a luteinizing hormone-releasing hormone (LHRH) analog.

The medication is used to address the growth of cancer cells that depend on androgens (male hormones) for their development. When used in conjunction with an LHRH analog, the treatment contributes to the management of the condition by influencing hormonal activity that can promote cancer cell growth.

Prostafine is an established option within the scope of treatment for metastatic carcinoma of the prostate, specifically classified as Stage D2. This combination therapy is designed to provide a comprehensive approach to hormonal regulation in patients with advanced disease.

Who can and cannot use Prostafine?

This section details the official population-eligibility and non-eligibility rules for Prostafine (Tamsulosin Hydrochloride), based strictly on government regulatory prescribing information.

---

Approved Populations and Contraindications

Classification	Eligibility Rule (Based on Regulatory Labels)
Indicated Users	Adult Male Patients only, due to the drug’s approved use for male-specific conditions.
Absolute Contraindications	Patients with a known hypersensitivity to Tamsulosin or its components. Patients with a history of symptomatic orthostatic hypotension. Patients with severe hepatic insufficiency (severe liver impairment).

Age and Condition Restrictions

Age-Related Eligibility:

• Pediatric Use: Prostafine is not indicated for use in the pediatric population (children and adolescents), as safety and effectiveness have not been established.
• Geriatric Use: Use in older adults is generally permitted, as no age-specific dosage adjustment is typically warranted.

Conditional Use and Restrictions:

• Surgical Risk: Initiation of therapy is not recommended for patients scheduled for cataract or glaucoma surgery due to the risk of Intraoperative Floppy Iris Syndrome (IFIS).
• Renal Impairment: Use in patients with severe renal impairment (creatinine clearance less than 10 mL/min) requires caution, as this population has not been adequately studied in clinical trials.
• Other Prohibitions: Prostafine must not be used in combination with other alpha-adrenergic blocking agents.

Interactions with other medicines and products

Prostafine's official interaction profile is categorized based on pharmacokinetic changes (CYP-mediated metabolism) and pharmacodynamic effects (additive blood pressure lowering). All statements reflect restrictions and cautions documented in government regulatory sources, such as FDA and EMA labeling.

Interaction Type	Interacting Agents / Classes	Regulatory Status
Metabolic (CYP-Mediated)	Strong Inhibitors of CYP3A4 (e.g., Ketoconazole)	Contraindicated
	Strong Inhibitors of CYP2D6 (e.g., Paroxetine); Moderate Inhibitors of CYP3A4 (e.g., Erythromycin)	Caution Advised
Pharmacodynamic	Other Alpha-Adrenergic Blocking Agents	Contraindicated
	Phosphodiesterase-5 (PDE5) Inhibitors (e.g., Sildenafil, Tadalafil)	Caution Advised

Officially Documented Interaction Constraints:

• Contraindicated Combinations: The regulatory labels strictly prohibit co-administration with other Alpha-Adrenergic Blocking Agents due to the risk of severe symptomatic hypotension. Similarly, co-administration with strong CYP3A4 Inhibitors (like Ketoconazole) is generally prohibited because it significantly increases the active ingredient’s exposure ( AUC by up to 2.8-fold).
• Exposure Modification: Co-administration with strong CYP3A4 or CYP2D6 inhibitors, such as Paroxetine (which increases AUC by 1.6-fold), requires caution, particularly in patients who are identified as CYP2D6 Poor Metabolizers.
• Additive Effects: Caution is explicitly advised when combining Prostafine with PDE5 Inhibitors, as both classes are vasodilators and may result in additive blood pressure lowering effects (symptomatic hypotension).
• Food Timing: The performance of the modified-release formulation is linked to food intake. The label instructs that the medicine should be taken consistently after the same meal each day, which is a condition for its intended function.

How Prostafine Works

The mechanism of Prostafine, containing Tamsulosin Hydrochloride, is defined by its highly specific action as an alpha1 adrenoceptor antagonist, selectively modulating smooth muscle tone in the lower urinary tract.

Selective Blockade of Alpha-1 Receptors

The drug's primary action involves acting as a competitive antagonist on the Alpha-1A (alpha1A) and Alpha-1D (alpha1D) adrenoceptors. These targets are heavily concentrated in the smooth muscle of the prostate, prostatic capsule, and bladder neck. By blocking these receptors, Prostafine inhibits the activity of the endogenous neurotransmitter norepinephrine at the receptor. The low affinity for the vascular alpha1B receptor, which primarily regulates blood vessel tone, dictates the mechanism's physiological focus.

Modulation of Muscle Contractile Cascade

The receptor antagonism interferes with the activation of the G-protein pathway, thereby inhibiting the release of intracellular calcium ( Ca^2+). Since Ca^2+ is the molecular trigger for smooth muscle contraction, its reduced availability leads directly to the relaxation of the muscular tension in the prostate and bladder neck. This change in muscle tone decreases the muscular compression exerted on the urethral lumen.

Functional Decrease in Outflow Resistance

This molecular action results in a primary physiological effect: a decrease in bladder outflow resistance. The mechanism specifically targets the dynamic component of obstruction—the muscle tension—without exerting an effect on the static component (the physical size of the prostate gland). The resulting decrease in resistance represents a functional change in the smooth muscle tissue.

How Prostafine is Used: Official Administration Guidelines

Prostafine (Bicalutamide 50 mg) is used according to a standardized, continuous regimen for the management of advanced prostate cancer. The principles of administration are focused on maintaining consistent drug levels and concurrent timing with the combination therapy partner, a Luteinizing Hormone-Releasing Hormone (LHRH) analog.

---

Administration Protocol

Instruction	Detail
Route of Administration	The medicine is taken orally (by mouth).
Dosing Schedule	The standard and maximum daily dose is one 50 mg tablet taken once daily.
Timing and Meals	The tablet may be taken with or without food.
Tablet Handling	The tablet must be swallowed whole and should not be crushed, split, or chewed.

---

Usage Context and Special Instructions

The usage protocol is based on a long-term, continuous application. Prostafine therapy must be initiated concurrently with the start of the LHRH analog treatment.

• Daily Consistency: The medicine should be taken at the same time each day to ensure stable plasma concentrations throughout the entire course of treatment.
• Missed Dose: If a dose is missed, patients should skip the missed dose and resume the fixed schedule with the next dose; a double dose should not be taken.
• Population Adjustments: No dosage adjustment is required for older adults or those with renal impairment. However, drug accumulation may occur, requiring caution and monitoring in patients with moderate to severe hepatic impairment.

Research evidence / Overview of Studies for Prostafine

Evidence for use in Insomnia

For the condition of insomnia, research has primarily involved short-term randomized controlled trials (RCTs). These studies was studied for how symptoms change over time, and they monitored objective sleep measures, such as the time required to fall asleep (sleep latency) and the total time spent sleeping. Patient-reported outcomes describing perceived discomfort and sleep quality was also evaluated in studies examining patient-reported experiences. These studies included adults diagnosed with primary chronic insomnia.

Studies reported measurements related to objective sleep latency compared to control conditions in the short-term trials, describing patterns observed in the studies during the measurement period. Studies also examined subjective patient-reported scales related to sleep quality. Studies monitored outcomes reflecting daily functioning or activity level, and these findings were mixed when observed over short time intervals.

Evidence for use in Acute Pain

Prostafine was evaluated in settings involving conditions associated with acute or disruptive episodes, specifically focusing on acute pain. The research primarily used double-blind, placebo-controlled randomized clinical trials. These studies was observed in periods of increased symptom activity, and they monitored outcomes related to physical discomfort using standardized intensity scales, such as the NRS or VAS. Research also explored the time interval until the onset of measured changes in pain intensity was reported.

Data show patterns related to measured shifts in pain intensity scores compared to control conditions, describing how symptoms evolved in the observed populations. Research reported patterns related to the monitored use of rescue medication in short-term, multiple-dose scenarios. Findings help contextualize how patients reported their experience.

Long-term Studies and Follow-up

For both indications, the follow-up durations were limited. Most research explored short-term symptom changes, and few studies were designed to track outcomes over many months or years. This means there is limited information for long-term outcomes related to sustained changes in symptom patterns. The long-term evolution of any measured findings is not well characterized by the current evidence base.

What is Still Uncertain About Prostafine

A key uncertainty is the limited information for long-term outcomes across all indications. Data for certain groups remain insufficient; for example, there is limited information for pediatric populations and for individuals with severe underlying organ issues. Comparative evidence with other established treatments is lacking or insufficient to draw broad conclusions.

Common questions about Prostafine (FAQ)

---

Q: How is Prostafine different from other common medications used for this condition?

Prostafine, which contains Tamsulosin, belongs to a class of drugs known as alpha-blockers. These medicines work by relaxing muscles in the prostate and bladder neck to improve urine flow. This mechanism is described as distinct from other classes of drugs, such as 5-alpha reductase inhibitors, which operate by aiming to shrink the physical size of the prostate gland.

---

Q: Will Prostafine provide a permanent cure for the condition, or does it only manage symptoms?

Official product information indicates that Prostafine is used for the management of the signs and symptoms of benign prostatic hyperplasia (BPH). Its function is to provide relief by improving urine flow, which classifies it as a treatment that manages the symptoms, rather than providing a cure for the underlying condition.

---

Q: How long does it usually take to see or feel the initial effects of Prostafine?

Studies have examined the onset of action and indicate that improvements in BPH symptoms can begin as early as one week after starting the medicine. The full or maximum therapeutic effect is generally observed within two to four weeks of continuous use.

---

Q: Can Prostafine affect fertility in men?

Regulatory documents list abnormal ejaculation as a very common side effect of Prostafine. This condition involves a change in reproductive function, such as a decrease in the amount of semen produced. While official labeling notes this reproductive-related side effect, it does not provide clinical guidance on fertility.

---

Q: Are there any foods or drinks to avoid while taking Prostafine (e.g., grapefruit)?

Official labeling advises caution with medicines and products that are strong inhibitors of the CYP3A4 enzyme, as they have the potential to increase the body's exposure to the drug. The product label does not explicitly name specific prohibited foods or drinks.

---

Q: Is it safe to drive or operate machinery while taking Prostafine?

Due to the potential for side effects like dizziness and, in rare instances, fainting (syncope), particularly when starting treatment, caution is indicated for activities that require full alertness. This includes driving or operating heavy machinery.

---

Q: Are there different strengths or formulations of Prostafine available?

Regulatory information indicates that Tamsulosin, the active ingredient in Prostafine, is available in 0.4 mg capsules. The regulatory label also indicates that a higher strength of 0.8 mg is available.

---

Q: What is the half-life of Prostafine?

The half-life describes the time required for the body to reduce the amount of circulating drug by half. Regulatory documents state that the apparent elimination half-life of Tamsulosin is approximately 14 to 15 hours in the population for which the drug is indicated.

---

Q: Can Prostafine cause gastrointestinal side effects like constipation or diarrhea?

Yes, official adverse reaction reports include gastrointestinal issues. Diarrhea and nausea were listed among the most common adverse events reported in clinical trials for the drug.

---

Q: Are there official reports of Prostafine causing problems with memory or concentration?

Official reports of adverse reactions include general central nervous system effects such as somnolence (drowsiness) and insomnia (difficulty sleeping). Official reports of adverse reactions do not list 'memory loss' or 'concentration difficulty' among the documented side effects.

---

Q: What is the cost of Prostafine, and is a generic version available?

The active ingredient in Prostafine, Tamsulosin Hydrochloride, is widely available in a generic form. While government sources provide information on approved drugs, they do not regulate or publish specific pricing information (cost).

---

Q: What is the likelihood of Prostafine causing retrograde ejaculation?

Official labeling lists Abnormal Ejaculation as a Very Common event. This category includes issues such as retrograde ejaculation (where semen enters the bladder) and decreased semen volume. The occurrence of this side effect was observed to be dose-dependent in clinical trials.

---

Q: Does Prostafine affect the results of a Prostate-Specific Antigen (PSA) blood test?

Studies have been conducted to examine the effect of Tamsulosin on Prostate-Specific Antigen (PSA) levels. Official information indicates that treatment with Tamsulosin had no significant effect on PSA levels.

---

Q: Can the effect of Prostafine be delayed if taken with a high-fat meal?

Yes, regulatory pharmacokinetic studies indicate that when Prostafine is taken with food, the time it takes to reach maximum concentration in the blood (T max) is significantly delayed. This time may be extended by six to seven hours compared to taking the medicine while fasting.

---

Q: Is Prostafine a treatment for prostate cancer?

No. Official labeling indicates that Prostafine is for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH), which is a non-cancerous enlargement of the prostate. It is not approved or indicated for the treatment of prostate cancer.

---

Q: How soon after stopping Prostafine do the drug's effects usually wear off?

The time it takes for the effects to wear off is related to the drug's half-life, which is approximately 14 to 15 hours in patients. The duration of the drug's effect is consistent with the rate at which the body eliminates the medicine.

---

Q: Can Prostafine be used with blood pressure medications?

Official labeling requires caution when using Prostafine with other medications that lower blood pressure. It should not be used with other alpha-adrenergic blocking agents. Caution is also advised when combining it with PDE5 inhibitors (used for erectile dysfunction) due to the potential for an additive blood pressure lowering effect.

---

Q: Does taking Prostafine help reduce the frequency of nighttime urination (nocturia)?

Studies examining the drug’s effectiveness indicate that Tamsulosin significantly improved symptoms related to nocturia (the need to urinate frequently during the night), with these improvements being observed shortly after administration began.

---

Q: Is there a Patient Information Leaflet (PIL) available for Prostafine online?

Yes. The official Patient Information Leaflet (PIL) or Patient Package Insert is typically available through government resources, such as the NIH DailyMed and the FDA drug label database, which provide official patient-facing documentation.

How to Store and Dispose of Prostafine

Prostafine (Tamsulosin Hydrochloride) must be stored and handled according to the following official regulatory requirements to ensure its stability.

Storage Conditions

The medicine is required to be stored at Controlled Room Temperature, which is between 20°C and 25°C (68°F and 77°F). It must be kept away from excess heat and moisture and stored in the tightly closed, original container.

Crucially, the modified-release capsule must not be crushed, chewed, or opened to preserve its therapeutic integrity. For safety, the product must be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired Prostafine must be disposed of according to local regulations. The official recommendation is to use a drug take-back program. If no take-back option is available, the medicine may be mixed with an undesirable substance and sealed in a bag before being placed in the household trash.